EACS 2025 was an essential meeting for the numerous presentations about PrEP that included far more than news about injectable formulations, which for all their promise, are still hardly used by anyone.
Cabotegravir-LA (CAB-LA) and lenacapavir (LEN) are important of course, but the most sobering results related to the current limited access to oral PrEP, reported in a plenary lecture by Teymur Noori from the ECDC on Europe’s uncertain health targets.
Ten years after FTC/TDF was approved by the EMA, PrEP is only being widely used in a few countries, with many barriers and inequalities even to low-priced generics.
These details need to be taken together with the announcement that the EACS guidelines now support event-based dosing for everyone.
Read the full news story at HIV i-Base.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.